BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2016

View Archived Issues

NIH begins phase I clinical testing of investigational Zika vaccine

Read More

Tribendimidine shows promise for the treatment of O. viverrini infections

Read More

University of Dundee reports compounds to treat leishmaniasis

Read More

Medshine Discovery discloses heat shock protein inhibitors

Read More

Massachusetts General Hospital and the HHS patent mRNA-targeting compounds

Read More

Katholieke Universiteit Leuven and Ortho-McNeil-Janssen Pharmaceuticals present antiviral compounds

Read More

Dana-Farber Cancer Institute and Whitehead Institute divulge dehydrogenase inhibitors

Read More

Galecto Biotech patents galectin inhibitors

Read More

Intec Pharma to develop Accordion Pill tetrahyrocannabidiol/cannabidiol

Read More

Omeros' lead MASP-3 inhibitor shows efficacy in arthritis model

Read More

DNAtrix receives grant from FDA for phase II trial in glioblastoma

Read More

Abeona Therapeutics cleared to conduct phase I/II study of gene therapy for MPS IIIA in Europe

Read More

Momenta discontinues further accrual of its phase II trial of necuparanib in pancreatic cancer

Read More

Vaxart begins phase I trial of oral norovirus tablet vaccine

Read More

Astellas reviews pipeline progress of first quarter of fiscal 2016

Read More

Shionogi updates pipeline developments of first quarter of fiscal 2016

Read More

Ono Pharmaceutical reports product and pipeline progress of first quarter of fiscal 2016

Read More

Microbion's MBN-101 earns FDA fast track designation for diabetic foot ulcer infections

Read More

AAV2 gene therapy shows promising safety and efficacy in inherited blindness

Read More

Juno Therapeutics enters into partnership with MSK and Eureka Therapeutics

Read More

ScinoPharm and CVie Therapeutics collaborate to develop new heart failure drug

Read More

Palatin Technologies gives update on bremelanotide phase III studies for HSDD

Read More

Artesunate inhibits ocular neovascularization in animal models

Read More

Griffith University and Olymvax Biopharmaceuticals to develop Group A Streptococcus vaccine

Read More

Carna Biosciences and Janssen Biotech to terminate license agreement

Read More

Rosetta Genomics launches OncoGxSelect

Read More

Quest Diagnostics launches new digital dementia assessment test for cognitive dysfunction

Read More

Bellicum Pharmaceuticals' BPX-501 and rimiducid granted orphan drug designation in Europe

Read More

Researchers initiate study to identify mutation prevalence in hereditary pancreatic cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing